<DOC>
	<DOCNO>NCT00452842</DOCNO>
	<brief_summary>An observational safety follow trial conduct monitor occurrence cardiovascular event cause mortality subject participate select torcetrapib/atorvastatin Phase 1 , 2 , 3 clinical trial . No hypothesis test .</brief_summary>
	<brief_title>Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies</brief_title>
	<detailed_description>Study A5091075 , observational study subject previously treat torcetrapib , terminate 20 Dec 2007 . The study terminate follow review final safety information prior torcetrapib study low participation rate observe recruitment period study A5091075 . On basis new information Sponsor determine unlikely study would result new scientifically valid information .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Have sign inform consent prior initiation studyspecific activity . Have participate select torcetrapib/atorvastatin Phase 1 , 2 , 3 clinical trial treat randomized study medication . There exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>